Oncotarget

Research Papers:

MDC and BLC are independently associated with the significant risk of early stage lung adenocarcinoma

Yanwei Zhang, Keke Yu, Song Hu, Yuqing Lou, Chunxing Liu, Jianlin Xu, Rong Li, Xueyan Zhang, Huimin Wang and Baohui Han _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:83051-83059. https://doi.org/10.18632/oncotarget.13031

Metrics: PDF 527 views  |   HTML 1291 views  |   ?  


Abstract

Yanwei Zhang1, Keke Yu2, Song Hu3, Yuqing Lou1, Chunxing Liu4, Jianlin Xu1, Rong Li1, Xueyan Zhang1, Huimin Wang1, Baohui Han1

1Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China

2Department of Biobank, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China

3Department of Research Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, PR China

4Department of Laboratory Medicine, Huadong Sanatorium, Wuxi, Jiangsu Province, PR China

Correspondence to:

Baohui Han, email: xkyyhan@gmail.com

Keywords: early stage lung adenocarcinoma, subcentimeter lung adenocarcinoma, inflammatory biomarkers

Received: August 17, 2016    Accepted: October 05, 2016    Published: November 03, 2016

ABSTRACT

Background: This prospective study was designed to investigate the association between ten circulating inflammatory biomarkers and the risk for early stage lung adenocarcinoma. Methods: All inflammatory biomarkers were measured in 228 patients with early stage (IA to IIB) lung adenocarcinoma and 228 age-, sex- and smoking-matched healthy controls by using the Luminex bead-based assay. Results: Only two biomarkers were significantly associated with the risk of early stage lung adenocarcinoma after the Bonferroni correction: the multivariate odd ratio (OR) (95% confidence interval or CI) was 0.29 (0.16-0.53) for MDC and 4.17 (2.23-7.79) for BLC for the comparison of patients in the 4th quartile with the 1st quartile (both P<0.0001). When analysis was restricted to never smokers (196 patients/196 controls), MDC and BLC were still significantly associated with the risk of early stage lung adenocarcinoma (OR, 95% CI, P: 0.37, 0.21-0.66, P<0.0001 for MDC and 2.78, 1.48-5.22, P =0.001 for BLC). Furthermore, elevated BLC was associated with a 2.90-fold (95% CI: 1.03-8.17, P=0.037) increased risk of subcentimeter lung adenocarcinoma, and there was an increasing trend for BLC with the progression of subcentimeter lung adenocarcinoma. Conclusion: Our findings demonstrated that MDC and BLC were independently associated with the significant risk of early stage lung adenocarcinoma, even in non-smokers and in stage IA patients. BLC was further identified to play a carcinogenic role in the progression of lung adenocarcinoma.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 13031